Mitophagy in Parkinson's Disease: Pathogenic and Therapeutic Implications
- PMID: 29046661
- PMCID: PMC5632845
- DOI: 10.3389/fneur.2017.00527
Mitophagy in Parkinson's Disease: Pathogenic and Therapeutic Implications
Abstract
Neurons affected in Parkinson's disease (PD) experience mitochondrial dysfunction and bioenergetic deficits that occur early and promote the disease-related α-synucleinopathy. Emerging findings suggest that the autophagy-lysosome pathway, which removes damaged mitochondria (mitophagy), is also compromised in PD and results in the accumulation of dysfunctional mitochondria. Studies using genetic-modulated or toxin-induced animal and cellular models as well as postmortem human tissue indicate that impaired mitophagy might be a critical factor in the pathogenesis of synaptic dysfunction and the aggregation of misfolded proteins, which in turn impairs mitochondrial homeostasis. Interventions that stimulate mitophagy to maintain mitochondrial health might, therefore, be used as an approach to delay the neurodegenerative processes in PD.
Keywords: Parkinson disease; autophagosome; mitochondria; mitophagy; synuclein.
Similar articles
-
Mitophagy and Alzheimer's Disease: Cellular and Molecular Mechanisms.Trends Neurosci. 2017 Mar;40(3):151-166. doi: 10.1016/j.tins.2017.01.002. Epub 2017 Feb 9. Trends Neurosci. 2017. PMID: 28190529 Free PMC article. Review.
-
Dysfunctional Mitochondria and Mitophagy as Drivers of Alzheimer's Disease Pathogenesis.Front Aging Neurosci. 2019 Nov 20;11:311. doi: 10.3389/fnagi.2019.00311. eCollection 2019. Front Aging Neurosci. 2019. PMID: 31824296 Free PMC article. Review.
-
The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.Biochim Biophys Acta. 2014 Jan;1842(1):7-21. doi: 10.1016/j.bbadis.2013.10.003. Epub 2013 Oct 11. Biochim Biophys Acta. 2014. PMID: 24120997
-
Mitophagy in Parkinson's Disease: From Pathogenesis to Treatment.Cells. 2019 Jul 12;8(7):712. doi: 10.3390/cells8070712. Cells. 2019. PMID: 31336937 Free PMC article. Review.
-
The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.Int J Mol Sci. 2019 Oct 25;20(21):5312. doi: 10.3390/ijms20215312. Int J Mol Sci. 2019. PMID: 31731450 Free PMC article. Review.
Cited by
-
Modulation of Mitochondrial Dynamics in Neurodegenerative Diseases: An Insight Into Prion Diseases.Front Aging Neurosci. 2018 Nov 5;10:336. doi: 10.3389/fnagi.2018.00336. eCollection 2018. Front Aging Neurosci. 2018. PMID: 30455640 Free PMC article. Review.
-
Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson's Disease "Off" Episodes.Health Psychol Res. 2022 Jun 28;10(3):36074. doi: 10.52965/001c.36074. eCollection 2022. Health Psychol Res. 2022. PMID: 35774903 Free PMC article.
-
Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation.Transl Neurodegener. 2020 Jun 1;9(1):19. doi: 10.1186/s40035-020-00197-z. Transl Neurodegener. 2020. PMID: 32475349 Free PMC article. Review.
-
Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson's Disease.Pharmaceutics. 2022 Nov 19;14(11):2514. doi: 10.3390/pharmaceutics14112514. Pharmaceutics. 2022. PMID: 36432705 Free PMC article. Review.
-
Interactions of amyloidogenic proteins with mitochondrial protein import machinery in aging-related neurodegenerative diseases.Front Physiol. 2023 Nov 2;14:1263420. doi: 10.3389/fphys.2023.1263420. eCollection 2023. Front Physiol. 2023. PMID: 38028797 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources